Future Prospects of Global Laboratory Proficiency Testing Market

Cushing's syndrome is characterised by high blood pressure, reddish stretch marks, abdominal obesity, round red face, weak muscles, weak bones, a fat hump between the shoulders, and fragile skin that heals slowly as a result of extended cortisol exposure. Cushing's syndrome is caused by two main factors: excessive cortisol-like medicines, such as prednisone, and tumours generated by adrenal glands overproducing cortisol. Other tumours, such as those associated with hereditary illnesses such multiple endocrine neoplasia type 1 and Carney complex, may also cause this condition. In most situations, a combination of surgery, radiation, and chemotherapy can be used to treat and cure the cancer.
Intake of glucocorticoids recommended by a healthcare professional to treat other disorders such as asthma, rheumatoid arthritis, or immunosuppression following an organ transplant is the most common cause of Cushing's syndrome. The disease can also be caused by the use of synthetic ACTH. Other animals, such as cats, dogs, and horses, may also be affected. All of the aforementioned causes are projected to boost the Cushing's syndrome market.
Cushing’s Syndrome
Market- Regional Analysis
Cushing's syndrome is divided into five regions: North
America, Europe, Asia-Pacific, the Middle East, Latin America, and Africa. The
presence of a high income standard and a high level of health awareness in
North America encourages the expansion of the market for Cushing's syndrome.
Obesity is a primary cause of Cushing's syndrome, according to the Centers for
Disease Control and Prevention, with 36.5 percent of individuals in the United
States having it between 2011 and 2014. Furthermore, according to the American
Diabetes Association, African Americans, Latin Americans, and Asian Pacific
Islanders are the most likely to develop type 2 diabetes.
Cushing’s Syndrome
Market- Competitive Landscape
Increased research and development in 2016, like
Strongbrigde Biopharma plc's development of clinical trials for RECORLEV for
the treatment of endogenous Cushing's syndrome, is expected to increase
competition and favour growth among manufacturers to lead the market. Corcept
Therapeutics Inc., HRA Pharma, Strongbridge Biopharma plc., and Novartis AG are
among the leading companies in the Cushing's syndrome industry.
Comments
Post a Comment